Amgen
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
Track Amgen in real time with a live news feed covering Amgen stock news, official press releases, company announcements, and an archive of historical Amgen news. ...more
Loading news...
Loading more...
8:10 AM | Saturday | Aug 15, 2026
Sign in to download news snippet
The bull market that started in 2022 still continues, making the market somewhat overvalued, and we recommend proven strategies over investing in what is popular. A SWAN (Sleep Well At Night) income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning, especially suited for income investors and retirees. We provide a framework for a long-term portfolio with multiple buckets that is flexible to suit individual needs, limitations, and preferences.
Read full articleNo data available for this time period.
Change the time range to see results.
The bull market that started in 2022 still continues, making the market somewhat overvalued, and we recommend proven strategies over investing in what is popular. A SWAN (Sleep Well At Night) income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning, especially suited for income investors and retirees. We provide a framework for a long-term portfolio with multiple buckets that is flexible to suit individual needs, limitations, and preferences.
Read full article
Baby Boomers building retirement income want two things from a dividend stock: a check that shows up on schedule, and a balance sheet that says the check will still show up ten years from now.
Read full article
Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 candidates in the pipeline.
Read full article
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Read full article
Generating $86,400 a year in dividends sounds like a number reserved for the ultra-wealthy, but the capital required swings dramatically depending on one variable most investors overlook before they build a single position.
Read full article
First Bank and Trust decreased its position in Amgen Inc. (NASDAQ: AMGN) by 15.5% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,014 shares of the medical research company's stock after selling 2,013 shares during the period.
Read full article
Amgen Inc. (NASDAQ: AMGN - Get Free Report) SVP Nancy Grygiel sold 2,970 shares of the company's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20.
Following the completion of the transaction, the senior vice president owned 7,340 shares in the
Reaching $13,000 a month in dividends sounds like a capital problem, but the real trap is choosing the wrong yield tier and watching income quietly erode while you sleep. Three buckets can get you there, each with a very different cost hiding beneath the headline number.
Read full article
Abner Herrman and Brock LLC decreased its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 24.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,418 shares of the medical research company's stock after selling 2,680 shares during the period.
Read full article
The market has finally noticed Amgen's R&D achievements and progress in commercializing its key blockbusters in the treatment of cardiovascular diseases and IMIDs. So, sales of Tezspire, used to treat asthma and CRSwNP, rose 42.1% year-over-year to $486 million in the second quarter. On the other hand, Repatha, a PCSK9 inhibitor, generated $953 million in revenue for Amgen, up 8.8% quarter-on-quarter.
No data available for this time period.
Change the time range to see results.